KR840001139A - Method for preparing 3-amino- [1] benzazin-2-one-1-alkanoic acid - Google Patents

Method for preparing 3-amino- [1] benzazin-2-one-1-alkanoic acid Download PDF

Info

Publication number
KR840001139A
KR840001139A KR1019820003588A KR820003588A KR840001139A KR 840001139 A KR840001139 A KR 840001139A KR 1019820003588 A KR1019820003588 A KR 1019820003588A KR 820003588 A KR820003588 A KR 820003588A KR 840001139 A KR840001139 A KR 840001139A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
alkyl
formula
alkoxy
Prior art date
Application number
KR1019820003588A
Other languages
Korean (ko)
Other versions
KR890003425B1 (en
Inventor
더블유·에이취·와테이 제프리
Original Assignee
아놀드 세일러, 에른스트 알테르
시바 가이기 아크티엔 계젤샤프트
에른스트 알테르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아놀드 세일러, 에른스트 알테르, 시바 가이기 아크티엔 계젤샤프트, 에른스트 알테르 filed Critical 아놀드 세일러, 에른스트 알테르
Publication of KR840001139A publication Critical patent/KR840001139A/en
Priority to KR1019890006489A priority Critical patent/KR900001195B1/en
Priority to KR1019890006487A priority patent/KR900001191B1/en
Priority to KR1019890006488A priority patent/KR900001192B1/en
Priority to KR8906486A priority patent/KR900001190B1/en
Application granted granted Critical
Publication of KR890003425B1 publication Critical patent/KR890003425B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음No content

Description

3-아미노-[1]벤즈아제핀-2-온-1-알카노산의 제조방법Method for preparing 3-amino- [1] benzazin-2-one-1-alkanoic acid

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (17)

a) 다음 일반식(Ⅱ)의 화합물중에 환원제 존재하에서 치환기 X,RA,RB,R,R3,R4및 R5중 어느 하나에 존재하는 어떤 1급 및 2급 아미노그룹 및/또는 임의로 하이드록시 및/또는 옥소그룹을 일시적으로 보호하고, 다음 일반식(ⅢA)의 화합물 또는 다음 일반식(Ⅳ)의 화합물로 알킬화하여 RA를 유도하거나 또는 b) 다음 일반식(Ⅴ)의 화합물을 잔기 X,RA,RB,R3,R4및 R5중 어느 하나에 존재하는 어떤 1급 및 2급 아미노그룹 및/또는 임의로 하이드록시 및/또는 옥소그룹을 일시적으로 보호하고, 다음 일반식(ⅢB)의 화합물로 알킬화 하거나 또는 c) 다음 일반식(Ⅵ)의 화합물(단, Y가 옥소인 경우 환원제 존재하에 치환기 X로서 존재하는 옥소그룹을 일시적으로 보호하고) 다음 일반식(Ⅶ)의 아민과 축합하거나, 또는 d) 다음 일반식(Ⅷ)의 화합물중 시아노그룹(들)을 가용매 분해하거나 또는 e) 다음 일반식(Ⅸ)의 화합물 또는 이의 에스테르를 고리화반응시키거나 또는 f) 다음 일반식(I)의 화합물과 구조적으로 동일한 화합물(단, 3번 탄소에 위치한 부가적인 이중결합, 또는 질소원자와 그룹 RA내의 인접한 탄소원자 사이의 부가적인 이중결합은 제외)을 환원제로 처리하여 이중결합을 포화시키거나 또는 g) X가 옥소인 다음 일반식(I)의 화합물을 생성시키기 위하여 다음 일반식(X)의 화합물을 다음 일반식(Ⅶ)의 아민과 축합시키고, h) 바람직하다면, 다음 일반식(I)의 생성된 화합물을 다음 범위내의 일반식(I)의 다른 화합물로 전환시키고 또는 i) 바람직하다면, 염-형성의 특징을 가지는 다음 일반식 (I)의 생성된 화합물을 이의 염으로 전환시키거나 또는 그와같은 염으로부터 유리형의 화합물을 유리시키고/또는 j) 바람직하다면, 착화합물-형성의 특징을 가지는 다음 일반식(I)의 생성된 화합물을 이의 착화합물로 전환시키고 또는 k) 필요하다면, 적어도 1개의 키랄(chiral)중심을 가지는 특수한 전자배치의 광학 이성체는 다음 일반식(I)의 생성된 화합물의 입체 이성체 혼합물로부터 보충함을 특징으로 하는 일반식(I)의 3-아미노-[1] 벤즈아제핀-2-온-1-알카노산, 이의 염, 착화합물 및 입체이성체를 제조하는 방법.a) any primary and secondary amino group present in any one of the substituents X, R A , R B , R, R 3 , R 4 and R 5 in the presence of a reducing agent in a compound of formula (II) Optionally temporarily protects the hydroxy and / or oxo group and alkylates with a compound of formula (IIIA) or a compound of formula (IV) to derive R A , or b) a compound of formula (V) Temporarily protects any primary and secondary amino groups and / or optionally hydroxy and / or oxo groups present in any one of residues X, R A , R B , R 3 , R 4 and R 5 , and Alkylated with a compound of formula (IIIB), or c) a compound of formula (VI), provided that if Y is oxo temporarily protect the oxo group present as substituent X in the presence of a reducing agent Or condensed with an amine of d), or d) the cyano group (s) Solvolysis or e) cyclization of a compound of formula (I) or an ester thereof or f) a compound structurally identical to a compound of formula (I), A double bond or an additional double bond between a nitrogen atom and an adjacent carbon atom in group R A ) is treated with a reducing agent to saturate the double bond, or g) a compound of formula (I) To produce a compound of the general formula (X) condensed with an amine of the general formula (h); and h) if desired, the resulting compound of the general formula (I) is different from the general formula (I) Or i) if desired, converting the resulting compound of formula (I) having salt-forming characteristics into a salt thereof or releasing a free-form compound from such a salt and / or j ) Bar If appropriate, convert the resulting compound of formula (I), which is characterized by complex-forming, into its complex or k) if necessary, the optical isomer of a special electron arrangement having at least one chiral center. 3-amino- [1] benzazin-2-one-1-alkanoic acid, salts, complexes thereof of formula (I), characterized in that they are supplemented from stereoisomeric mixtures of the resulting compounds of formula (I) And methods of preparing stereoisomers. 상기식에서In the above formula RA및 RB는 다음 식의 기이고R A and R B are groups of the formula (여기서 각각 R0는 카복시 또는 기능적으로 변형된 카복시이고; R1은 수소, 저급알킬, 아미노(저급)알킬, 아릴(저급)알킬, 사이클로알킬 또는 사이클로알킬(저급)알킬이며; R2는 수소 또는 저급알킬이다)Wherein each R 0 is carboxy or functionally modified carboxy; R 1 is hydrogen, lower alkyl, amino (lower) alkyl, aryl (lower) alkyl, cycloalkyl or cycloalkyl (lower) alkyl; R 2 is hydrogen Or lower alkyl) R3및 R4는 각각 수소, 저급알킬, 저급알콕시, 저급알카노일옥시, 하이드록시, 할로겐, 트리플루오로메틸이거나 또는 함께 저급알킬렌디옥시이며; R5는 수소 또는 저급알킬이고; X는 옥소, 2개의 수소, 또는 1개의 수소와 함께 1개의 하이드록시이고, 카보사이클릭환은 헥사하이드로 또는 6,7,8,9-테트라하이드로이며; Z는 반응성 에스테트화된 하이드록실 그룹이고; RA'는 수소 또는 전술한 RA이고; Y는 옥소 또는 수소와 함께 반응성 에스테르화된 하이드록시 그룹 Z이며; R0' 및 R0"중 하나는 시아노이고 다른 하나는 시아노 또는 전술한 R0이다.R 3 and R 4 are each hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, hydroxy, halogen, trifluoromethyl or together lower alkylenedioxy; R 5 is hydrogen or lower alkyl; X is 1 hydroxy with oxo, 2 hydrogen, or 1 hydrogen, and the carbocyclic ring is hexahydro or 6,7,8,9-tetrahydro; Z is a reactive esterified hydroxyl group; R A ′ is hydrogen or R A described above; Y is a reactive esterified hydroxy group Z with oxo or hydrogen; One of R 0 ′ and R 0 ″ is cyano and the other is cyano or R 0 described above. 제1항에 있어서, 기RA중에 COR6으로 나타내는 R0및 기 RB중 COR7로 나타내는 R0중의 하나가 또는 둘다 각각 카복시, 에스테르화된 카복시, 카바모일 또는 치환된 카바모일인 일반식(I)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.The general formula of claim 1, wherein one or both of R 0 represented by COR 6 in group R A and R 0 represented by COR 7 in group R B are each carboxy, esterified carboxy, carbamoyl or substituted carbamoyl. A process for preparing the compound of (I), a salt thereof, or a complex compound. 제2항에 있어서, R6및 R7중의 하나가 또는 둘다 하이드록시, 저급알콕시, (아미노, 모노-또는 디-저급알킬아미노)-치환된 저급알콕시, 카복시-치환된 저급알콕시, 저급알콕시카보님-치환된 저급알콕시, 아릴-치환된 저급알콕시(하이드록시, 저급알카노일옥시 또는 저급알콕시)-치환된 저급알콕시, (하이드록시, 저급알카노일옥시 또는 저급알콕시)-치환된 저급 알콕시메톡시, 바이사이클로 알콕시카보닐-치환된 저급알콕시, 3-프탈리독시, (저급알킬, 저급알콕시, 할로)-치환된 3-프탈리독시, 아미노, 저급알킬아미노, 디-저급알킬아미노, 디-저급알킬아미노(양 알킬그룹은 탄소원자에 의해 탄소결합에 연결되고 아미노 질소와 함께 5,6-또는 7-원 헤테로사이클릭환을 형성한다), (아미노 또는 아실아미노)-치환된 저급알킬아미노, α-(카복시 또는 저급알콕시카보닐)-치환된 저급알킬아미노, 아릴-치환된 저급알킬아미노(α-탄소중에 카복시 또는 저급알콕시카보닐로 치환될 수 있다)인 일반식(I)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.3. The compound of claim 2, wherein one or both of R 6 and R 7 are hydroxy, lower alkoxy, (amino, mono- or di-lower alkylamino) -substituted lower alkoxy, carboxy-substituted lower alkoxy, lower alkoxycarbo Nim-substituted lower alkoxy, aryl-substituted lower alkoxy (hydroxy, lower alkanoyloxy or lower alkoxy) -substituted lower alkoxy, (hydroxy, lower alkanoyloxy or lower alkoxy) -substituted lower alkoxymethoxy , Bicyclo alkoxycarbonyl-substituted lower alkoxy, 3-phthalidoxy, (lower alkyl, lower alkoxy, halo) -substituted 3-phthalidoxy, amino, lower alkylamino, di-lower alkylamino, di- Lower alkylamino (both alkyl groups are linked to a carbon bond by carbon atoms and form together with the amino nitrogen a 5,6- or 7-membered heterocyclic ring), (amino or acylamino) -substituted lower alkylamino , α- (carboxy or lower alkoxy To prepare a compound of formula (I), a salt or a complex thereof, which is carbonyl) -substituted lower alkylamino, aryl-substituted loweralkylamino (which may be substituted with carboxy or lower alkoxycarbonyl in α-carbon) Way. c) 다음 일반식(Ⅱ')의 화합물을 환원적 알킬화 조건하에서 다음 일반식(Ⅳ')의 화합물과 축합시키거나, 또는 알킬화 조건하에서 일반식(Ⅱ')의 화합물을 다음 일반식(ⅢA)의 화합물과 축합시키고, d) 생성물을 임의로 가수분해하거나 또는 유도체화하고, e) 다음 일반식(IA)의 생성된 화합물을 본 발명의 다른 화합물로 전환시키거나, 또는 b) 염기성 촉매작용의 조건하에서 다음 일반식(V')의 화합물을 다음 일반식(ⅢB)의 화합물과 축합시키고, c) 생성물을 임의로 가수분해하거나 또는 유도체화하고, d) 일반식(I)의 생성된 화합물을 임의로 본 발명의 다른 화합물로 전환시키거나, 또는 a) 다음 일반식(Ⅶ')의 화합물을 환원적 N-알킬화 조건하에서 다음 일반식(Ⅵ')의 화합물과 축합시키거나 또는 다음 일반식(ⅡA')의 화합물을 다음 일반식(Ⅵ')의화합물(여기서 X"는 옥소이고, Y는 수소 및 1개의 반응적으로 에스테르화된 또는 에테르화된 하이드록시이다)과 또는 이의 3,4-탈수소 제거 생성물과 또는 이의 3,4-탈수소유도체와 축합시키고, b) 생성물을 임의로 환원, 가수분해 또는 유도체화하고, c) 생성된 화합물을 임의로 본 발명의 다른 화합물로 전환시키고/또는 필요하다면, 생성된 유리형의 화합물을 염 또는 착화합물로, 또는 생성된 염을 유리형의 화합물 또는 다른 염으로 전환시키고, 필요하다면, 수득한 이성체 또는 라세미 화합물의 혼합물을 단(single)이성체 또는 라세미 화합물로 분해하고, 필요하다면 수득한 라세미 화합물을 광학적 대장체로 분해하여, 일반식(IA)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.c) condensation of a compound of formula (II ') with a compound of formula (IV') under reductive alkylation conditions or a compound of formula (II ') Condensation with a compound of, d) optionally hydrolyzing or derivatizing the product, e) converting the resulting compound of formula (IA) to another compound of the invention, or b) conditions of basic catalysis Under condensation of a compound of formula (V ′) with a compound of formula (IIIB), c) optionally hydrolyzing or derivatizing the product, d) optionally seeing the resulting compound of formula (I) Converted to another compound of the invention, or a) a compound of formula (VII ') is condensed with a compound of formula (VI') under reductive N-alkylation conditions or a formula (IIA ') To a compound of the general formula (VI '), wherein X ″ is oxo and Y is hydrogen and one reactively esterified or etherified hydroxy) or a 3,4-dehydrogenation product thereof or with a 3,4-dehydrogen derivative thereof, b ) The product is optionally reduced, hydrolyzed or derivatized, c) the resulting compound is optionally converted to another compound of the invention and / or if necessary, the resultant free-form compound is converted into a salt or a complex, or Conversion to free compounds or other salts, if necessary, the mixture of isomers or racemic compounds obtained is decomposed into single isomers or racemic compounds, and if necessary the racemic compounds are decomposed into optical colons , A process for preparing a compound of formula (IA), a salt thereof, or a complex compound. 상기 식에서In the above formula R1은 수소, 저급알킬, 아미노(저급)알킬, 아릴, 아릴(저급)알킬; 사이클로알킬(저급)알킬이고; R2및 R5은 수소 또는 저급알킬이며; R3및 R4는 수소, 저급알킬, 저급알콕시, 저급알카노일옥시, 하이드록시, 할로겐, 트리플루오로메틸이거나 또는 함께 저급알킬렌디옥시이고; X는 옥소, 2개의 수소 또는 1개의 하이드록시그룹 및 1개의 수소이고; R6및 R7은 각각 하이드록시, 아미노, 모노-또는 디-(저급)알킬아미노, 저급알콕시, 아릴(저급)알콕시, 저급알카노일옥시메톡시, (아미노, 모노-또는 디-저급알킬아미노, 카복시 또는 저급알콕시카보닐)-저급알콕시이고; R3' 및 R4'은 수소, 저급알킬, 저급알콕시, 저급알카노일옥시, 할로겐, 트리플루오로메틸이거나 또는 함께 저저급알킬렌 디옥시이고; X'는 2개의 수소, 1개의 수소 및 1개의 에테르화된 또는 에스테르화된 하이드록시, 옥소 또는 케탈 또는 티오케탈의 형태로 보호된 옥소이고;R 1 is hydrogen, lower alkyl, amino (lower) alkyl, aryl, aryl (lower) alkyl; Cycloalkyl (lower) alkyl; R 2 and R 5 are hydrogen or lower alkyl; R 3 and R 4 are hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, hydroxy, halogen, trifluoromethyl or together lower alkylenedioxy; X is oxo, two hydrogens or one hydroxy group and one hydrogen; R 6 and R 7 are hydroxy, amino, mono- or di- (lower) alkylamino, lower alkoxy, aryl (lower) alkoxy, lower alkanoyloxymethoxy, (amino, mono- or di-loweralkylamino, respectively) , Carboxy or lower alkoxycarbonyl) -lower alkoxy; R 3 ′ and R 4 ′ are hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, halogen, trifluoromethyl or together lower alkylene dioxy; X 'is oxo protected in the form of two hydrogens, one hydrogen and one etherified or esterified hydroxy, oxo or ketal or thioketal; R2' 및 R5'는 수소 또는 저급알킬이며; R6'는 하이드록시, 디(저급)알킬아미노, 저급알콕시, 아틸(저급)알콕시, 저급알카노일옥시메톡시 또는 저급알콕시카보닐(저급)알콕시이며; R7'는 하이드록시, 아미노, 모노-또는 디(저급)-알킬아미노, 저급알콕시, 아릴(저급)알콕시, 저급 알카노일옥시메톡시, 디(저급알킬아미노) 저급알콕시 또는 저급 알콕시카보닐(저급) 알콕시이고; R1'는 수소, 저급알킬, 아실화된 아미노(저급)알킬, 아릴, 아릴(저급)알킬, 사이클로알킬(저급)알킬이고; Z는 반응적으로 에스테르화된 하이드록시이고; R1"는 수소, 저급알킬, 아실화된 아미노(저급)알킬, 아릴, 아릴(저급)알킬, 사이클로알킬(저급)알킬이며; R2"는 수소 또는 저급알킬이고; R3"'및 R4"는 수소, 저급알킬, 저급알콕시, 저급알카노일옥시, 할로겐, 트리플루오로메틸이거나 또는 함께 저급 알킬렌디옥시이며; R5"는 수소 또는 저급알킬이고; R6"는 수소, 디(저급)알킬아미노, 저급알콕시, 아릴(저급)알콕시, 저급알카노일옥시메톡시 또는 저급알콕시카보닐(저급)알콕시이고; R7"는 하이드록시, 디(저급)알킬아미노, 저급알콕시, 아릴(저급)알콕시, 저급알카노일옥시메톡시 또는 저급 알콕시카보닐(저급)알콕시이며;R 2 ′ and R 5 ′ are hydrogen or lower alkyl; R 6 ′ is hydroxy, di (lower) alkylamino, lower alkoxy, atyl (lower) alkoxy, lower alkanoyloxymethoxy or lower alkoxycarbonyl (lower) alkoxy; R 7 ′ is hydroxy, amino, mono- or di (lower) -alkylamino, lower alkoxy, aryl (lower) alkoxy, lower alkanoyloxymethoxy, di (lower alkylamino) lower alkoxy or lower alkoxycarbonyl ( Lower) alkoxy; R 1 ′ is hydrogen, lower alkyl, acylated amino (lower) alkyl, aryl, aryl (lower) alkyl, cycloalkyl (lower) alkyl; Z is reactively esterified hydroxy; R 1 "is hydrogen, lower alkyl, acylated amino (lower) alkyl, aryl, aryl (lower) alkyl, cycloalkyl (lower) alkyl; R 2 " is hydrogen or lower alkyl; R 3 "'and R 4 " are hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, halogen, trifluoromethyl or together lower alkylenedioxy; R 5 ″ is hydrogen or lower alkyl; R 6 ″ is hydrogen, di (lower) alkylamino, lower alkoxy, aryl (lower) alkoxy, lower alkanoyloxymethoxy or lower alkoxycarbonyl (lower) alkoxy; R 7 ″ is hydroxy, di (lower) alkylamino, lower alkoxy, aryl (lower) alkoxy, lower alkanoyloxymethoxy or lower alkoxycarbonyl (lower) alkoxy; X"는 2개의 수소, 1개의 수소 및 1개의 에테르화된 또는 에스테르화된 하이드록시, 옥소 또는 케탈 또는 티오케탈의 형태로 보호된 옥소이고; Y는 옥소 또는 디클로로이다.X ″ is oxo protected in the form of two hydrogens, one hydrogen and one etherified or esterified hydroxy, oxo or ketal or thioketal; Y is oxo or dichloro. 제4항에 있어서, R1이 수소, 저급알킬, 아미노(저급)알킬, 아릴(저급)알킬(아릴은 저급알킬, 하이드록시, 저급알콕시, 저급알킬렌디옥시, 저급 알킬노일옥시, 할로겐 또는 트리플루오로메틸로 모노-또는 디-치환된 또는 비치환된 페닐이다)이고, R2및 R5가 수소 또는 저급알킬이며, R3및 R4가 수소, 저급알콕시, 저급알킬, 할로겐 또는 트리플루오로메틸이거나 또는 함께 알킬렌 디옥시이며, X가 옥소, 1개의 하이드록시 및 1개의 수소, 또는 2개의 수소이고, R6및 R7이 각각 하이드록시, 아미노, 저급알콕시, 페닐(저급)알콕시, 저급알콕시카보닐(저급)알콕시인 일반식(IA)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.5. The compound of claim 4, wherein R 1 is hydrogen, lower alkyl, amino (lower) alkyl, aryl (lower) alkyl (aryl is loweralkyl, hydroxy, loweralkoxy, loweralkylenedioxy, lower alkylnoyloxy, halogen or tri Phenyl mono- or di-substituted or unsubstituted with fluoromethyl), R 2 and R 5 are hydrogen or lower alkyl, R 3 and R 4 are hydrogen, lower alkoxy, lower alkyl, halogen or trifluor Romethyl or alkylene dioxy together, X is oxo, one hydroxy and one hydrogen, or two hydrogen, R 6 and R 7 are hydroxy, amino, lower alkoxy, phenyl (lower) alkoxy, respectively. And lower alkoxycarbonyl (lower) alkoxy. A method for producing a compound of formula (IA), a salt or a complex thereof. 제4항에 있어서, R1이 수소, 저급알킬, ω-아미노(저급)알킬, 아릴(저급)알킬(아릴은 저급알킬, 하이드록시, 저급알콕시, 저급 알카노일옥시, 할로겐 또는 트리플루오로 메틸로 모노-치환된 또는 비치환된 페닐이다)이고, R2및 R5가 수소 또는 저급알킬이고, R3및 R4가 수소, 저급알콕시, 저급알킬, 할로겐 또는 트리플루오로 메틸이거나 또는 함께 저급알킬렌디옥시이며, X가 옥소, 1개의 하이드록시 및 1개의 수소, 또는 2개의 수소이고, R6및 R7이 각각 하이드록시, 아미노, 저급알콕시, 페닐(저급)알콕시, 저급알콕시카보닐(저급) 알콕시인 일반식(IA)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.5. The compound of claim 4 wherein R 1 is hydrogen, lower alkyl, ω-amino (lower) alkyl, aryl (lower) alkyl (aryl is loweralkyl, hydroxy, loweralkoxy, lower alkanoyloxy, halogen or trifluoro methyl Mono-substituted or unsubstituted phenyl), R 2 and R 5 are hydrogen or lower alkyl, R 3 and R 4 are hydrogen, lower alkoxy, lower alkyl, halogen or trifluoro methyl or together lower Alkylenedioxy, X is oxo, 1 hydroxy and 1 hydrogen, or 2 hydrogen, R 6 and R 7 are hydroxy, amino, lower alkoxy, phenyl (lower) alkoxy, lower alkoxycarbonyl ( Lower) alkoxy, a process for the preparation of compounds of formula (IA), salts or complexes thereof. 제4항에 있어서, 다음 일반식(IB)의 화합물, 이의 염 또는 착화합물을 제조하는 방법.The process of claim 4, wherein the compound of formula (IB), a salt thereof, or a complex compound thereof is prepared. 상기 식에서In the above formula n은 1 내지 4의 정수이고; R8은 수소, 저급알킬, 저급알콕시, 저급알카노일옥시, 할로겐, 하이드록시 또는 트리플루오로메틸로 모노 치환된 또는 비치환된 페닐이고; R6및 R7은 각각 하이드록시, 탄소수 4까지의 저급알콕시, 벤질옥시 또는 아미노이다.n is an integer from 1 to 4; R 8 is phenyl mono-substituted or unsubstituted with hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, halogen, hydroxy or trifluoromethyl; R 6 and R 7 are hydroxy, lower alkoxy up to 4 carbon atoms, benzyloxy or amino, respectively. 제4항에 있어서, 1-카복시메틸-3-(1-에톡시카보닐-3-페닐 프로필아미노)-2,3,4,5-테트라하이드로-1H-[1] 벤즈아제핀-2-은, 이의 염 또는 입체이성체를 제조하는 방법.5. The compound of claim 4 wherein 1-carboxymethyl-3- (1-ethoxycarbonyl-3-phenyl propylamino) -2,3,4,5-tetrahydro-1H- [1] benzazin-2- Silver, a method for producing a salt or stereoisomer thereof. 제4항에 있어서, 제8항에서 명명한 화합물의 고용점을 가지는 라세미 화합물, 이의 광학적 대장체 또는 염을 제조하는 방법.The method of claim 4, wherein the racemic compound, the optical colon or salt thereof, having a solid solution point of the compound named in claim 8. 제4항에 있어서, 제8항에서 명명한 화합물의 저용점을 가지는 라세미 화합물, 이의 광학적 대장체 또는 염을 제조하는 방법.The method of claim 4, wherein the racemic compound, the optical colon or salt thereof, having a low melting point of the compound named in claim 8. 제4항에 있어서, 1-카복시메틸-3S-(1S-에톡시카보닐-3-페닐프로필아미노)-2,3,4,5-테트라하이드로-1H-[1]벤즈아제핀-2-온 또는 이의 염을 제조하는 방법.5. The compound of claim 4 wherein 1-carboxymethyl-3S- (1S-ethoxycarbonyl-3-phenylpropylamino) -2,3,4,5-tetrahydro-1H- [1] benzazin-2- Method of preparing a ions or salts thereof. 제4항에 있어서, 1-카복시메틸-3-(1-카복시-3-페닐프로필아미노)-2,3,4,5-테트라하이드로-1H-[1] 벤즈아제핀-2-은, 이의 염 또는 입체 이성체를 제조하는 방법.The compound according to claim 4, wherein 1-carboxymethyl-3- (1-carboxy-3-phenylpropylamino) -2,3,4,5-tetrahydro-1H- [1] benzazin-2- is Process for preparing salts or stereoisomers. 제4항에 있어서, 1-카복시메틸-3S-(1S-카복시-3-페닐프로필아미노)-2,3,4,5-테트라하이드로-1H-[1] 벤즈아제핀-2-은 또는 이의 염을 제조하는 방법.The compound according to claim 4, wherein 1-carboxymethyl-3S- (1S-carboxy-3-phenylpropylamino) -2,3,4,5-tetrahydro-1H- [1] benzazin-2-silver or its How to prepare a salt. 제4항에 있어서, 1-에톡시카보닐메틸-3-(1-카복시-3-페닐프로필아미노)-2,3,4,5-테트라하이드로-1H-[1]벤즈아제핀-2-은, 이의 염 또는 입체 이성체를 제조하는 방법.The method of claim 4, wherein 1-ethoxycarbonylmethyl-3- (1-carboxy-3-phenylpropylamino) -2,3,4,5-tetrahydro-1H- [1] benzazin-2- Silver, a method for producing a salt or stereoisomer thereof. 제4항에 있어서, 제14항에서 명명한 화합물의 라세미 이성체 화합물 B 또는 이의 염을 제조하는 방법.The process of claim 4, wherein the racemic isomeric compound B or salt thereof of the compound named in claim 14 is prepared. 제1항에 있어서, 1-카복시메틸-7-클로로-3-(1-에록시카보닐-3-페닐프로필아미노)-2,3,4,5-테트라하이드로-1H-[1]벤즈아제핀-2-은의 라세미 이성체 화합물 B 또는 이의 염을 제조하는 방법.The compound according to claim 1, wherein 1-carboxymethyl-7-chloro-3- (1-hydroxycarbonyl-3-phenylpropylamino) -2,3,4,5-tetrahydro-1H- [1] benzase A process for preparing racemic isomer compound B or a salt thereof of pin-2-silver. 제1항에 있어서, 3-(1-벤질옥시카보닐-3-페닐프로필아미노)-1-카복시메틸-2,3,4,5-테트라하이드로-1H-[1]벤즈아제핀-2-은, 이의 염 또는 입체 이성체를 제조하는 방법.The compound of claim 1, wherein 3- (1-benzyloxycarbonyl-3-phenylpropylamino) -1-carboxymethyl-2,3,4,5-tetrahydro-1H- [1] benzazin-2- Silver, a method for producing a salt or stereoisomer thereof. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR8203588A 1981-08-11 1982-08-10 Process for preparing 3-amino-(1)benzazepin-2-one-1-alkanoic acids KR890003425B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019890006489A KR900001195B1 (en) 1982-08-10 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR1019890006487A KR900001191B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR1019890006488A KR900001192B1 (en) 1982-08-10 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR8906486A KR900001190B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29190781A 1981-08-11 1981-08-11
US291,907 1981-08-11
US31986381A 1981-11-09 1981-11-09
US319,863 1981-11-09

Related Child Applications (4)

Application Number Title Priority Date Filing Date
KR1019890006487A Division KR900001191B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR8906486A Division KR900001190B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR1019890006488A Division KR900001192B1 (en) 1982-08-10 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR1019890006489A Division KR900001195B1 (en) 1982-08-10 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid

Publications (2)

Publication Number Publication Date
KR840001139A true KR840001139A (en) 1984-03-28
KR890003425B1 KR890003425B1 (en) 1989-09-20

Family

ID=26967047

Family Applications (3)

Application Number Title Priority Date Filing Date
KR8203588A KR890003425B1 (en) 1981-08-11 1982-08-10 Process for preparing 3-amino-(1)benzazepin-2-one-1-alkanoic acids
KR1019890006487A KR900001191B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR8906486A KR900001190B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1019890006487A KR900001191B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid
KR8906486A KR900001190B1 (en) 1981-08-11 1989-05-13 Preparation process for 3-amino-(1)benzazepin-2-one-1-alkanoic acid

Country Status (22)

Country Link
EP (1) EP0072352B1 (en)
KR (3) KR890003425B1 (en)
AR (3) AR240806A1 (en)
AT (1) ATE18397T1 (en)
AU (1) AU561395B2 (en)
CA (1) CA1196636A (en)
CY (1) CY1403A (en)
DD (1) DD202546A5 (en)
DE (1) DE3269625D1 (en)
DK (1) DK157881C (en)
ES (6) ES8502974A1 (en)
FI (1) FI76074C (en)
GB (1) GB2103614B (en)
GR (1) GR77256B (en)
HK (1) HK93387A (en)
HU (1) HU189628B (en)
IE (1) IE53668B1 (en)
IL (1) IL66501A (en)
NL (1) NL930112I2 (en)
NO (1) NO161558C (en)
NZ (1) NZ201555A (en)
PT (1) PT75395B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3242599A1 (en) * 1982-11-18 1984-05-24 Dr. Karl Thomae Gmbh, 7950 Biberach NEW BENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
US4473575A (en) * 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
DE3373469D1 (en) * 1982-09-30 1987-10-15 Merck & Co Inc 1-n-alkylcarboxy-benzofused lactams useful as antihypertensive agents
US4575503A (en) * 1983-02-10 1986-03-11 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4564612A (en) * 1983-04-22 1986-01-14 Takeda Chemical Industries, Ltd. Condensed, seven-membered ring compounds and their use
US4539150A (en) * 1983-06-29 1985-09-03 Mitsui Toatsu Chemicals, Inc. Benzothiazepine derivatives and their methods of preparation
JPS608284A (en) * 1983-06-29 1985-01-17 Mitsui Toatsu Chem Inc Benzothiazepine derivative and its preparation
AU570710B2 (en) * 1983-08-12 1988-03-24 Takeda Chemical Industries Ltd. 4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzoxazepine derivatives
US4638000A (en) * 1983-08-12 1987-01-20 Takeda Chemical Industries, Ltd. Condensed seven-membered ring compounds, their production and use
IL72523A (en) * 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
CA1266647A (en) * 1984-06-26 1990-03-13 William H. Parsons Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists
DE3586445T2 (en) * 1984-06-26 1993-01-14 Merck & Co Inc CONDENSED BENZO LACTAM COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS.
EP0166357A3 (en) * 1984-06-26 1988-10-26 Merck & Co. Inc. Benzofused lactams and pharmaceutical compositions containing them
US4785089A (en) * 1985-06-13 1988-11-15 Ciba-Geigy Corporation Novel sulfonic acid esters and their preparation
DE3704661A1 (en) * 1987-02-14 1988-08-25 Hoechst Ag FELECTED AZEPINONE AND AZOCINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR CONTAINERS AND THEIR USE, AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION
EP0322779A3 (en) * 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
TW197945B (en) * 1990-11-27 1993-01-11 Hoechst Ag
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
GB9212308D0 (en) * 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
JPH08505374A (en) * 1992-12-11 1996-06-11 チバ−ガイギー アクチェンゲゼルシャフト Benzazepinone derivative
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
US5801168A (en) * 1994-06-09 1998-09-01 Zeneca Limited Substituted nitrogen heterocycles
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
EP1229913A4 (en) * 1999-11-18 2005-01-19 Antexpharma Inc Substituted 1-benzazepines and derivatives thereof
EP2256104A1 (en) 2000-12-27 2010-12-01 Merck Patent GmbH Process for the preparation of alpha-aminosubstituted carboxylic acid amides
JP2004526735A (en) 2001-03-27 2004-09-02 ランバクシー ラボラトリーズ リミテッド Method for producing benazepril
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20050107359A1 (en) * 2002-07-26 2005-05-19 Van Der Schaaf Paul A. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
KR100710548B1 (en) * 2002-12-26 2007-04-24 에스케이 주식회사 Method for preparing s-3-amino-2,3,4,5- tetrahydro-2-oxo-1H-1-benzazepin-1-acetic acid and ester compound thereof
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US8080579B2 (en) 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
JP2010508358A (en) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー Glucocorticoid receptor, AP-1 and / or modulator of NF-κB activity, and use thereof
ES2393885T7 (en) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN113292495B (en) * 2021-06-18 2022-09-13 迪嘉药业集团有限公司 Synthesis method of (S) -amino compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3395150A (en) * 1965-02-26 1968-07-30 Squibb & Sons Inc Benzothiazepine carboxamides and derivatives thereof
GB1305278A (en) * 1970-03-12 1973-01-31

Also Published As

Publication number Publication date
NO161558C (en) 1989-08-30
DK157881C (en) 1990-07-23
IL66501A (en) 1987-10-20
NL930112I2 (en) 1996-11-01
ES514856A0 (en) 1985-02-01
AU8701482A (en) 1983-05-12
AR240806A1 (en) 1991-02-28
AR240806A2 (en) 1991-02-28
AR240807A2 (en) 1991-02-28
NL930112I1 (en) 1993-10-18
ES526887A0 (en) 1986-04-16
AR241222A1 (en) 1992-02-28
AR240807A1 (en) 1991-02-28
NO161558B (en) 1989-05-22
KR890003425B1 (en) 1989-09-20
PT75395B (en) 1985-11-15
ES8504728A1 (en) 1985-04-16
DE3269625D1 (en) 1986-04-10
KR900001191B1 (en) 1990-02-28
CA1196636A (en) 1985-11-12
IE53668B1 (en) 1989-01-04
ES526886A0 (en) 1985-11-01
IE821929L (en) 1983-02-11
KR900001190B1 (en) 1990-02-28
DK157881B (en) 1990-02-26
ES8604523A1 (en) 1986-02-01
FI822770L (en) 1983-02-12
ES8602682A1 (en) 1985-12-01
IL66501A0 (en) 1982-12-31
ES526889A0 (en) 1986-02-01
EP0072352A1 (en) 1983-02-16
DK358682A (en) 1983-02-12
ATE18397T1 (en) 1986-03-15
FI822770A0 (en) 1982-08-09
GR77256B (en) 1984-09-11
ES530658A0 (en) 1985-12-01
NO822722L (en) 1983-02-14
FI76074B (en) 1988-05-31
CY1403A (en) 1987-12-18
DD202546A5 (en) 1983-09-21
EP0072352B1 (en) 1986-03-05
ES8601142A1 (en) 1985-11-01
FI76074C (en) 1988-09-09
HK93387A (en) 1987-12-18
AU561395B2 (en) 1987-05-07
GB2103614A (en) 1983-02-23
ES526888A0 (en) 1985-04-16
HU189628B (en) 1986-07-28
ES8606285A1 (en) 1986-04-16
NZ201555A (en) 1986-06-11
PT75395A (en) 1982-09-01
GB2103614B (en) 1984-11-21
ES8502974A1 (en) 1985-02-01

Similar Documents

Publication Publication Date Title
KR840001139A (en) Method for preparing 3-amino- [1] benzazin-2-one-1-alkanoic acid
TW374086B (en) Prostaglandin I2 agonistic oxazole compounds and the process for preparing thereof
KR830010104A (en) Method for preparing an arylphenyl ether derivative
ATE20469T1 (en) CARBOXYALKYL DIPEPTIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THEM.
NZ237132A (en) Preparation of substituted oxetanones from beta-hydroxy-omega-lactones; various beta-hydroxy and beta-keto-omega-lactones
Suami et al. The revised structure of validamycin A
ES8306160A1 (en) New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds.
ZA943493B (en) Ketone 5-ht4 receptor antagonists
CA2085503A1 (en) Process for preparing 2-chloro-2'-deoxyadenosine
DK98183D0 (en) METHOD OF PREPARING 1,2,4-TRIAZOL COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS THEREOF
IE50885B1 (en) 1-phenyl-2-cyclohexene-1-alkylamine derivatives,a process for their preparation and medicaments containing them
ES8703477A1 (en) New tetracyclo compounds, a process for their production and a pharmaceutical composition containing the same.
EP0398749A3 (en) Polyisocyanatoalkylphenyl-isocyanurates, method for the preparation thereof and use thereof
KR890009915A (en) Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compound
PT96003A (en) METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING A TRIAZOL DERIVATIVE
ES8203877A1 (en) Process for producing 1-position amino-derivatives of 1-(3',4'-methylenedioxyphenyl)propane-2-ol
KR910004632A (en) Novel 1-oxa-2-oxo-8-azaspiro [4,5] decane derivatives, pharmaceutical compositions comprising them and methods for preparing the same
US3817994A (en) Substituted (phenyl) (2-oxazolidinyl) and (phenyl) (2-tetrahydrooxazinyl) ketones and lower alkanols
US4367341A (en) Antiatherosclerotic 7-substituted methoxyfurochromones
ES2130394T3 (en) PROCEDURE TO PRODUCE PROVITAMINE D COMPOUNDS.
ES8603871A1 (en) +/- 2-(Phenethyl)-5-((3,4-methylenedioxy)-alpha-hydroxybenzyl)-pyrrolidines, pharmaceutical compositions containing them, processes for their production and intermediates therefor.
US4532340A (en) Furochromone intermediates
US3891665A (en) {60 ,3-Diphenyl-2-oxazolidinemethanol compounds
HUT53093A (en) Process for producing substituted 3-amino-sidnonimine derivatives and pharmaceutical compositions them as active components
US4025512A (en) 6A-Azacannabinoids

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010818

Year of fee payment: 13

EXPY Expiration of term